Valence8 US LP Purchases New Position in Ascendis Pharma A/S (NASDAQ:ASND)

Valence8 US LP bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 4,585 shares of the biotechnology company's stock, valued at approximately $685,000. Ascendis Pharma A/S accounts for approximately 0.3% of Valence8 US LP's investment portfolio, making the stock its 15th largest holding.

Other institutional investors also recently modified their holdings of the company. Signaturefd LLC increased its stake in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock valued at $102,000 after acquiring an additional 80 shares during the last quarter. Bessemer Group Inc. increased its stake in Ascendis Pharma A/S by 61.0% in the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company's stock valued at $132,000 after purchasing an additional 332 shares in the last quarter. Pursue Wealth Partners LLC acquired a new stake in Ascendis Pharma A/S in the third quarter worth $217,000. Searle & CO. bought a new position in shares of Ascendis Pharma A/S during the second quarter worth $205,000. Finally, Rhumbline Advisers grew its holdings in shares of Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock valued at $209,000 after buying an additional 143 shares during the period.

Ascendis Pharma A/S Trading Up 5.2 %

NASDAQ ASND traded up $6.36 during midday trading on Friday, hitting $129.00. The company had a trading volume of 269,690 shares, compared to its average volume of 449,826. Ascendis Pharma A/S has a twelve month low of $90.13 and a twelve month high of $161.00. The firm has a 50-day moving average price of $133.01 and a 200-day moving average price of $132.26. The company has a market capitalization of $7.82 billion, a PE ratio of -15.22 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. On average, equities analysts anticipate that Ascendis Pharma A/S will post -7.45 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ASND shares. Wedbush restated an "outperform" rating and set a $181.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, November 15th. StockNews.com upgraded shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research note on Wednesday. Citigroup lifted their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a "buy" rating in a research report on Tuesday, September 17th. Cantor Fitzgerald reissued an "overweight" rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Finally, The Goldman Sachs Group raised their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a "buy" rating in a research note on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $191.77.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.